Navigation Links
Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
Date:5/17/2013

SAN DIEGO, May 17, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the UBS Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, May 22nd at 11 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2019)... (PRWEB) , ... August 21, 2019 , ... ... patron experience by lowering pool chemical use with Clear Comfort’s Advanced Oxidation Process ... able to save significant chemical expense dollars, simplify its water care protocol and ...
(Date:8/19/2019)... ... , ... Like so many senior executives in complex industries, a former Procter & Gamble Vice ... to talk about it. He turned a make-it-or-break-it opportunity — debating his company’s biggest ... speaking events. , On Monday, September 9, 2019 at 12pm EDT (5pm BST/UK), join ...
(Date:8/19/2019)... ... August 19, 2019 , ... Physician Partners of ... join its Richardson, Texas location, starting Monday, Sep. 2nd. , Dr. Spiro Khoury ... subspecialty board certification in pain management. , Dr. Khoury attended the American University ...
Breaking Medicine Technology:
(Date:8/21/2019)... ... August 21, 2019 , ... ISOComforter , a leader in providing products for ... , The system starts with a powered cold unit supply that is shaped ... are compatible with the unit, such as the shoulder pad, lumbar pad, hip wrap, or ...
(Date:8/19/2019)... ... August 19, 2019 , ... American Society ... and cosmetic procedures in 2018 – 7.5 percent more than 2017 and a ... ASDS Survey on Dermatologic Procedures revealed skin cancer treatments are persistently ...
(Date:8/19/2019)... ... August 18, 2019 , ... ... launches its third product, Aqua+, adding two SKUs to its line of functional ... and more effectively than water alone. Distinguishing Aqua+ from other rehydration solutions is ...
(Date:8/16/2019)... ... ... The clinical trial supply chain landscape is constantly shifting, and clinical professionals ... Time Manufacturing Solutions Manager at Almac Clinical Services , Natalie Balanovsky, in a ... on a journey through time as it relates to clinical trial supply. , ...
(Date:8/15/2019)... , ... August 15, 2019 , ... ... to pathology residents who have been directly affected by the closure of Hahnemann ... of donations gathered during the campaign, the ASCP Foundation will be making hardship ...
Breaking Medicine News(10 mins):